Ireland: IPHA And The Government Finally Reach Agreement On The Supply And Pricing Of Medicines In Ireland

Last Updated: 22 August 2016
Article by Colin Kavanagh and Ciara Farrell
Most Read Contributor in Ireland, October 2018

On 20 July 2016, following much debate and lengthy negotiations, the Irish Government, the Health Service Executive ("HSE") and the Irish Pharmaceutical Healthcare Association ("IPHA") signed the Framework Agreement on the Supply and Pricing of Medicines (the "Agreement") .

SCOPE

The new Agreement, which came into effect on 1 August 2016, governs the supply and pricing of medicinal products that are included on the HSE Reimbursement List , supplied to, or reimbursed by, the HSE, State-funded hospitals or any other publicly-funded entities and State agencies providing similar services ("Hospital Medicines"), or subject to an application for inclusion on the Reimbursement List, or for supply or reimbursement as a Hospital Medicine.

APPLICATION TO NON-IPHA MEMBERS

The previous Agreement stated that the agreement applied to "all suppliers" of products that fall within the scope above. However, the 2012 Agreement did not define the term "supplier" nor did it differentiate between IPHA member companies and non-IPHA member companies.

The new Agreement applies only to IPHA member companies (listed in Schedule 2 of the Agreement). The HSE and IPHA member companies may now only rely on the provisions of the new Agreement by agreement.

We would anticipate that many non- IPHA members will take account of the pricing criteria in the new Agreement when submitting an application for pricing approval or come to their own arrangements with the HSE. This would not depart radically from previous practice under the 2012 Agreement.

ENFORCEABILITY

Section 21(2) of the Health (Pricing and Supply of Medical Goods) Act 2013 (the "2013 Act") allows the HSE to take account of a number of different factors, only one of which is the terms of the Agreement, when considering the proposed price of a product submitted by a supplier.

The Agreement purports to reflect this position by stating that the Agreement does not create legal relations or legitimate expectations which can be enforced by or against the parties. The Agreement also states that it will not limit the HSE's powers under the 2013 Act, allowing the HSE to take into account other factors when assessing the proposed price of a medicinal product.

KEY CHANGES

Outlined below are a number of notable differences between the new more comprehensive Agreement and its predecessor.

Four year term

The Agreement is for a period of four years rather than the previous three year term.

Extension of the number of nominated EU Member States

Under the previous Agreement, prices were set at the average of the currency-adjusted ex-factory price (price to wholesaler) in nine EU Member States, namely, Austria, Belgium, Denmark, Finland, France, Germany, the Netherlands, Spain and the UK. The new Agreement introduces five additional EU Member States (Greece, Italy, Luxembourg, Portugal and Sweden), bringing the proposed price of a product in line with the average ex-factory price in 14 Member States.

Annual price realignment

All medicinal products will now be subject to an annual price realignment commencing on 1 August 2016 and on 1 July for each subsequent year. The price realignment will be set as the average ex-factory price of the 14 Member States.

The price realignments will be downwards only. The HSE and the suppliers should have agreed new prices for 2016 no later than 20 July 2016.

Rebates increase

Rebates from suppliers to the HSE for products will increase from 4% to 5.25% (1 June 2016 – 31 July 2018) and 5.5% (1 August 2018 – 31 July 2020) of the ex-factory price. It is intended that further guidance in relation to the payment and collection of rebates with regard to Hospital Medicines will be developed by the HSE and IPHA.

Reduction in price of patent-expired products

The price of a medicinal product that has lost patent protection and for which a generic product is available will fall to 50% of the original ex-factory price.

Similar to the 2012 Agreement, the HSE will notify the supplier when a generic medicinal product has become available and the date from which the new price will apply, which will be no less than 28 days following notification.

Reduction in price of patent-expired biological products

For the first time, the Agreement differentiates between generic medicinal products and biosimilar products when considering price reductions for patent-expired products. Patent-expired biological products will now be subject to a 20% reduction in price once a biosimilar enters the market.

In addition to the price cut and, unlike generic medicinal products, suppliers of biological products must pay the HSE a rebate of 12.5% of the value of the reduced price.

Penalties related to continuity of supply

Under the 2012 Agreement, suppliers in breach of the provisions related to continuity of supply, such as notice periods, were required to either source and supply alternative equivalent products at the same price as the unavailable product or reimburse the HSE any difference in cost arising from the shortage.

The new Agreement no longer includes this provision. However, the Agreement mentions that suppliers must adhere to the IPHA/HSE Statement of Best Practice for Notifying the Discontinuation of a Medicine from the Irish Market ("Best Practices") which still includes these penalties. Suppliers should monitor any amendments to the Best Practices.

Guidance and transparency when assessing new medicinal products

Schedule 1 of the Agreement sets out detailed principles and processes for the assessment of pricing and reimbursement of new products in Ireland. The new principles and processes provide some clarity and transparency with regard to the decision making structure and timelines. The new Agreement formalises the Annual Horizon Scan, the Rapid Review Process and provides clarity in relation to the HSE Drugs Group recommendations.

One of the most notable changes in the decision making process is the introduction of the role of the Department of Health and the Government when reviewing products which cannot be funded from within existing HSE resources, such as products that exceed the budget impact or a certain cost-effectiveness threshold. At the first instance, the HSE Leadership will assess such products. If the HSE cannot reimburse the product, the HSE can inform the Department of Health who, in turn, may apply to the Government to request consideration of the funding of the product. It is hoped that more clarity as to the practical application of such a high level review for specific products will be provided once the Agreement comes into force.

This article contains a general summary of developments and is not a complete or definitive statement of the law. Specific legal advice should be obtained where appropriate.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions